Initial Consideration. On the Effective Date, the Company shall grant the Licensor the following consideration (the “Initial Consideration”): (i) twenty-five million (25,000,000) Class C shares with a liquidation value of twenty cents ($0.20) per share; (ii) five million (5,000,000) Class B shares (10 votes per share) with a liquidation value of eighty cents ($0.80) per share; and (iii) eight million (8,000,000) Category 1 warrants to purchase within two (2) years Class A shares at an exercise price of forty cents ($0.40) per share.
Appears in 3 contracts
Sources: Technology License Agreement (Acasti Pharma Inc.), Prepayment Agreement (Acasti Pharma Inc.), Technology License Agreement (Neptune Technologies & Bioressources Inc.)